Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002939 · ClinicalTrials.gov registry record · Phase 1
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00002939 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by University of Chicago. The registered enrollment target is 21 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00002939, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and paclitaxel in treating patients with metastatic or recurrent cancer.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG irinotecan hydrochloride
Study Locations (1)
Illinois
- University of Chicago Cancer Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 1996-11 |
| Est. Completion | 2002-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002939
The ClinicalTrials.gov registry entry for NCT00002939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (96% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00002939 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00002939 about?
NCT00002939 is a clinical study titled "Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and paclitaxel in treating patients with metastatic or recu...
What is the current status of trial NCT00002939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 1996-11. Estimated completion is 2002-04.
What conditions does trial NCT00002939 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00002939?
The interventions under investigation include: paclitaxel (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002939?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002939 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.